12360 Federal Register / Vol. 76, No. 44 / Monday, March 7, 2011 / Notices 

understand and respond appropriately. 

The project activities and methods will 

remain the same as those used in the 

previously approved collection. 

Data are collected through 

anonymous, in-person interviews 

conducted with persons systematically 

selected from 25 Metropolitan Statistical 

Areas (MSAs) throughout the United 

States; these 25 MSAs were chosen 

based on having high AIDS prevalence. 

Persons at risk for HIV infection to be 

interviewed for NHBS include men who 

have sex with men (MSM), injecting 

drug users (IDUs), and heterosexuals at 

increased risk of HIV (HET). A brief 

screening interview will be used to 

determine eligibility for participation in 

the behavioral assessment. The data 

from the behavioral assessment will 

provide estimates of behavior related to 

the risk of HIV and other sexually 

transmitted diseases, prior testing for 

HIV, and use of HIV prevention 

services. All persons interviewed will 

also be offered an HIV test and will 

participate in a pre-test counseling 

session. No other federal agency 

systematically collects this type of 

information from persons at risk for HIV 

infection. These data have substantial 

impact on prevention program 

development and monitoring at the 

local, state, and national levels. 

CDC estimates that NHBS will 

involve, per year in each of the 25 

MSAs, eligibility screening for 50 to 200 

persons and eligibility screening plus 

the survey with 500 eligible 

respondents, resulting in a total of 

37,500 eligible survey respondents and 

7,500 ineligible screened persons during 

a 3-year period. Data collection will 

rotate such that interviews will be 

conducted among one group per year: 

MSM in year 1, IDU in year 2, and HET 

in year 3. The type of data collected for 

each group will vary slightly due to 

different sampling methods and risk 

characteristics of the group. 

This request is for a revision and an 

approval for an additional 3 years of 

data collection. Participation of 

respondents is voluntary and there is no 

cost to the respondents other than their 

time. The total estimated annualized 

burden hours are 9,931. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

respondents 

Responses per 

respondent 

Average burden 

per response; (in 

hours) 

Year 1 (MSM): 

Persons Screened ............................................................... Screener ................. 17,500 1 5/60 

Eligible Participants ............................................................. Survey ..................... 12,500 1 30/60 

Year 2 (IDU): 

Persons Referred by Peer Recruiters ................................. Screener ................. 13,750 1 5/60 

Eligible Participants ............................................................. Survey ..................... 12,500 1 54/60 

Peer Recruiters ................................................................... Recruiter Debriefing 6,250 1 2/60 

Year 3 (HET): 

Persons Referred by Peer Recruiters ................................. Screener ................. 13,750 1 5/60 

Eligible Participants ............................................................. Survey ..................... 12,500 1 39/60 

Peer Recruiters ................................................................... Recruiter Debriefing 6,250 1 2/60 

Petunia Gissendaner, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. 2011–5092 Filed 3–4–11; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket Number NIOSH–226] 

Request for Information on 

Implementation of the James Zadroga 

9/11 Health and Compensation Act of 

2010 (Pub. L. 111–347) 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH), Centers for Disease Control 

and Prevention (CDC), Department of 

Health and Human Services (HHS). 

ACTION: Notice of public comment 

period. 

SUMMARY: The National Institute for 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and Prevention (CDC) requests 

comments from the public on 

implementing the provisions of the 

James Zadroga 9/11 Health and 

Compensation Act of 2010 (Pub. L. 111– 

347). A copy of the Act is posted on the 

Internet at http://www.cdc.gov/niosh/ 

docket in the NIOSH Docket number 

226. The Federal government is 

developing an implementation plan, 

and comments from the public will 

assist in this process by gaining 

perspectives from interested parties on 

ways to meet the Act’s requirements. 

The public is invited to submit written 

comments to the NIOSH Docket number 

226. A public meeting on March 3, 

2011, was previously announced in the 

Federal Register (76 FR 7862) on 

February 11, 2011 to accept oral 

comments from the public. 

Public Comment Period: All 

comments must be received by April 29, 

2011. 

ADDRESSES: Written comments may be 

submitted to the NIOSH Docket Office, 

identified by Docket number NIOSH– 

226, by any of the following methods: 

• Mail: NIOSH Docket Office, Robert 

A. Taft Laboratories, MS–C34, 4676 

Columbia Parkway, Cincinnati, OH 

45226. 

• Facsimile: (513) 533–8285. 

• E-mail: nioshdocket@cdc.gov. 

All information received in response 

to this notice will be available for public 

examination and copying at the NIOSH 

Docket Office, Room 111, 4676 

Columbia Parkway, Cincinnati, Ohio 

45226. 

A complete electronic docket 

containing a copy of the James Zadroga 

9/11 Health and Compensation Act of 

2010 (Pub. L. 111–347) and all 

comments submitted will be available 

on the NIOSH Web site at http:// 

www.cdc.gov/niosh/docket. All 

comments received will be available for 

public inspection, including any 

personally identifiable or confidential 

business information that is included in 

a comment. Because comments will be 

made public, they should not include 

any sensitive personal information, such 

as a person’s social security number; 

date of birth; driver’s license number; 

state identification number or foreign 

country equivalent; passport number; 

financial account number; or credit or 

debit card number. Comments also 

should not include any sensitive health 

information, such as medical records or 

other individually identifiable health 


srobinson on DSKHWCL6B1PROD with NOTICES
Federal Register / Vol. 76, No. 44 / Monday, March 7, 2011 / Notices 12361 

information, or any non-public 

corporate or trade association 

information, such as trade secrets or 

other proprietary information. 

FOR FURTHER INFORMATION CONTACT: Roy 

Fleming, Sc.D., CDC/NIOSH, 1600 

Clifton Road, NE., MS–E20, Atlanta, 

Georgia 30333, Toll free 1–866–426– 

3673, e-mail: nioshdocket@cdc.gov. 

Dated: February 28, 2011. 

John Howard, 

Director, National Institute for Occupational 

Safety and Health, Centers for Disease Control 

and Prevention. 

[FR Doc. 2011–5111 Filed 3–4–11; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Determine of 

the Benefits of Work and/or School 

Exclusion to Respiratory Illness in 

Decreasing Influenza Transmission, 

Funding Opportunity Number (FOA) 

CK11–007, Initial Review 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the aforementioned meeting: 

Time and Date: 8 a.m.–5 p.m., May 2, 2011 

(Closed). 

Place: Sheraton Gateway Hotel Atlanta 

Airport, 1900 Sullivan Road, Atlanta, Georgia 

30337, Telephone: (770) 997–1100. 

Status: The meeting will be closed to the 

public in accordance with provisions set 

forth in Section 552b(c) (4) and (6), Title 5 

U.S.C., and the Determination of the Director, 

Management Analysis and Services Office, 

CDC, pursuant to Public Law 92–463. 

Matters To Be Discussed: [The meeting will 

include the initial review, discussion, and 

evaluation of applications received in 

response to ‘‘Determine of the Benefits of 

work and/or School Exclusion to Respiratory 

Illness in Decreasing Influenza 

Transmission’’] 

Contact Person for More Information: Dr. 

Amy Yang, Scientific Review Officer, CDC, 

1600 Clifton Road, NE., Mailstop E60, 

Atlanta, Georgia 30333, Telephone: (404) 

498–2733. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Dated: February 25, 2011. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2011–5102 Filed 3–4–11; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket Number NIOSH 134–A] 

Request for Information: Update of 

NIOSH Nanotechnology Strategic Plan 

for Research and Guidance 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and Prevention (CDC), 

Department of Health and Human 

Services (HHS). 

ACTION: Notice of public comment 

period. 

SUMMARY: National Institute for 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and Prevention (CDC) seeks 

comment on the types of hazard 

identification and risk management 

research that should be considered for 

updating the NIOSH 2009 

nanotechnology strategic plan. 

Public Comment Period: Comments 

must be received by April 15, 2011. 

ADDRESSES: Written comments, 

identified by docket number NIOSH 

134–A, may be submitted by any of the 

following ways: 

• Mail: NIOSH Docket Office, Robert 

A. Taft Laboratories, MS–C–34, 4676 

Columbia Parkway, Cincinnati, Ohio 

45226. 

• Facsimile: (513) 533–8285. 

• E-mail: nioshdocket@cdc.gov. 

All information received in response 

to this notice will be available for public 

examination and copying at the NIOSH 

Docket Office, 4676 Columbia Parkway, 

Room 109, Cincinnati, Ohio 45226. A 

complete electronic docket containing 

all comments submitted will be 

available thirty days after the public 

comment period on the NIOSH Web 

page at http://www.cdc.gov/niosh/ 

docket, and comments will be available 

in writing by request. NIOSH includes 

all comments received without change 

in the docket, including any personal 

information provided. All electronic 

comments should be formatted as 

Microsoft Word. Please make reference 

to docket number NIOSH 134–A. 

Background: Since 2004, the National 

Institute for Occupational Safety and 

Health (NIOSH) of the Centers for 

Disease Control and Prevention (CDC) 

has pioneered research on the 

toxicological properties and 

characteristics of nanoparticles. This 

research has involved characterizing 

occupationally relevant nanoparticles 

for predicting whether these particles 

pose a risk of adverse health effects and 

for providing guidance on controlling 

workplace exposures. In September 

2005, NIOSH developed a strategic plan 

to further guide the Institute in 

identifying and prioritizing 

nanotechnology research. In 2009 this 

strategic plan [http://www.cdc.gov/ 

niosh/topics/nanotech/strat_plan.html] 

was updated based on knowledge 

gained from results of ongoing NIOSH 

research [see Progress Toward Safe 

Nanotechnology in the Workplace; A 

Report from the NIOSH Nanotechnology 

Research Center http://www.cdc.gov/ 

niosh/docs/2007–123/] and from 

stakeholder input. 

NIOSH would like to build on the 

accomplishments of ongoing research 

[see http://www.cdc.gov/niosh/docs/

2010–104/] to develop strategic research 

goals and objectives through 2015. 

NIOSH has identified 10 critical 

research areas for nanotechnology 

research and communication. These 10 

critical research areas are (1) toxicity 

and internal dose, (2) measurement 

methods, (3) exposure assessment, (4) 

epidemiology and surveillance, (5) risk 

assessment, (6) engineering controls and 

personal protective equipment (PPE), (7) 

fire and explosion safety, (8) 

recommendations and guidance, (9) 

communication and information, and 

(10) applications. 

NIOSH is considering focusing the 

overarching strategic research goals for 

these critical areas on 5 key goals: (1) 

Provide guidance to protect workers, (2) 

alert workers, employers, governments, 

and the public about possible new 

hazards, (3) assess the hazards of 

nanomaterials and the risks to workers, 

(4) help workers by assessing and 

implementing exposure registries, and 

(5) assess the level of protection 

practiced in US workplaces. 

NIOSH requests comment on how 

research in these 10 critical areas and 

the 5 overarching goals can be 

enhanced. Examples of requested 

information include, but are not limited 

to: 

(1) The need for toxicity evaluation 

and/or workplace exposure 

characterization of engineered 

nanoparticles not currently being 

studied*. 


srobinson on DSKHWCL6B1PROD with NOTICES